Peer-reviewed article

Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?

Expert opinion on drug safetyApr 11, 2022Canada2 citationsDOI: 10.1080/14740338.2022.2063274

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinMDMADepressionPTSDAddiction

Keywords

Post-traumatic Stress DisorderSubstance Use DisordersMajor Depressive DisorderpsychotherapyPsychedelics

View paper Full text (PDF)

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

ArticlePsilocybin

Psychedelics and Mental Health in Endurance Athletes: A Cross-Sectional Study in Brazil.

Portes MAM, Bertoglio LJ

Europe PMC2026

ArticleMDMA

Aesthetic mediation and lateral agency: Rethinking trauma and drug consumption in 'crisis ordinariness'.

Fomiatti R, Keane H, Nourse G +4

Europe PMC2026